Vergent Bioscience is a clinical-stage biotechnology company that is helping surgeons realize the full potential of minimally invasive and robotic-assisted surgery by improving the visibility of tumors. Vergent’s lead compound, VGT-309, is a tumor-targeted fluorescent imaging agent intentionally designed to enable surgeons to see previously undetected or difficult-to-find tumors during surgery in real time, so they can ensure all tumor tissue is removed during surgery. The company is first evaluating VGT-309 in lung cancer, with the potential to expand its application to a wide range of solid tumors.
Highly differentiated agent unlocking the potential of real-time tumor visualization
A Strong Foundation to Transform Care
Bringing together an innovative investigational imaging agent, a commitment to rigorous science, and a world-class leadership team, Vergent Bioscience is positioned to become the global leader in intraoperative tumor visualization.